Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.

ABSTRACT:

Introduction

Sodium glucose cotransporter 2 (SGLT2) inhibitors have a unique mechanism of action leading to excretion of glucose in the urine and subsequent lowering of plasma glucose. This mechanism is independent of β-cell function; thus, these agents are effective treatment for type 2 diabetes mellitus (T2DM) at theoretically any disease stage. This class should not confer an additional risk of hypoglycemia (unless combined with insulin or an insulin secretagogue) and has the potential to be combined with other classes of glucose-lowering agents. Empagliflozin is one of three currently approved SGLT2 inhibitors in the United States, and has shown a favorable benefit-risk ratio in phase 3 clinical trials as monotherapy and as add-on to other glucose-lowering therapy in broad pati

SUBMITTER: Levine MJ 

PROVIDER: S-EPMC5543566 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature